Nat Rev Drug Discov. 2025 Jan 28. IF: 122.7FGF-based drug discovery: advances and challenges.www.nature.com/articles/s41573-024-01125-w Nat Rev Cancer. 2025 Jan 28. IF: 72.5Tumour hypoxia in driving genomic instability and tumour evolution.www.nature.com/articles/s41568-024-00781-9 Nature. 2025 Jan 28. IF: 50.5Breaking up clusters of circulating tumour cells to halt cancer spread.www.nature.com/articles/d41586-025-00251-8 J Clin Oncol. 2025 Jan 28. IF: 42.1You Don't Bring Me Flowers.www.ascopubs.org/doi/10.1200/JCO-24-02046 Nat Rev Cardiol. 2025 Jan 28. IF: 41.7Anthracycline-induced cardiomyopathy: risk prediction, prevention and treatment.www.nature.com/articles/s41569-025-01126-1 Nat Biotechnol. 2025 Jan 28. IF: 33.1A human metabolic map of pharmacological perturbations reveals drug modes of action.www.nature.com/articles/s41587-024-02524-5 Trends Immunol. 2025 Jan 27. IF: 13.1The 'inflammazone' in chronic inflammatory diseases: psoriasis and sarcoidosis.www.cell.com/trends/immunology/fulltext/S1471-4906(25)00002-X Drugs. 2025 Jan 28. IF: 13.0Inavolisib: First Approval.link.springer.com/article/10.1007/s40265-024-02136-y Nat Chem Biol. 2025 Jan 28. IF: 12.9The measurement, regulation and biological activity of FAHFAs.www.nature.com/articles/s41589-024-01827-7 JAMA Netw Open. 2025 Jan 28;8(1):e2457020. IF: 10.5Understanding of Clinical Trials Among Patients With Cancer and Their Relatives.www.jamanetwork.com/journals/jamanetworkopen/fullarticle/2829658 Radiol Med. 2025 Jan 28. IF: 9.7(18)F-FDG PET/CT radiomic analysis and artificial intelligence to predict pathological complete response after neoadjuvant chemotherapy in breast cancer patients.link.springer.com/article/10.1007/s11547-025-01958-4 Proc Natl Acad Sci U S A. 2025 Jan 28;122(5):e2416796122. IF: 9.4Triethylamine-mediated protonation-deprotonation unlocks dual-drug self assembly to suppress breast cancer progression and metastasis.www.pnas.org/doi/10.1073/pnas.2416796122 EMBO J. 2025 Jan 28. IF: 9.4Micropeptide hSPAR regulates glutamine levels and suppresses mammary tumor growth via a TRIM21-P27KIP1-mTOR axis.www.embopress.org/doi/10.1038/s44318-024-00359-z Cytokine Growth Factor Rev. 2025 Jan 23. IF: 9.3Interleukin-17: A pleiotropic cytokine implicated in inflammatory, infectious, and malignant disorders.www.sciencedirect.com/science/article/pii/S1359610125000024 NPJ Precis Oncol. 2025 Jan 28;9(1):25. IF: 6.8A morphometric signature to identify ductal carcinoma in situ with a low risk of progression.www.nature.com/articles/s41698-024-00769-6 Br J Cancer. 2025 Jan 28. IF: 6.4Semi-mechanistic efficacy model for PARP + ATR inhibitors-application to rucaparib and talazoparib in combination with gartisertib in breast cancer PDXs.www.nature.com/articles/s41416-024-02935-w Nat Rev Bioeng. 2025 Jan 28. IF: N/AClinical translation of personalized bioengineered implant scaffolds.www.nature.com/articles/s44222-024-00269-z Life Metab. 2025 Jan 27;4(1):loae041. IF: N/APCSK9 V474I germline variant drives breast cancer metastasis.www.academic.oup.com/lifemeta/article/7942712 Mol Ther Oncol. 2025 Jan 27. IF: N/AMiRNA-dependent resistance mechanisms to anti-hormonal therapies in Estrogen receptor-positive breast cancer patients.www.cell.com/molecular-therapy-family/oncology/fulltext/S2950-3299(25)00010-4
